Overview

Caduet and TLC Intervention in Metabolic Syndrome

Status:
Completed
Trial end date:
2016-02-28
Target enrollment:
Participant gender:
Summary
To evaluate the effectiveness of Caduet in addition to therapeutic life-style change (TLC) intervention in resolving metabolic syndrome fifty three individuals were randomized to TLC intervention study with or without Caduet therapy for 12 months. The participants underwent monthly visits with investigators to obtain vital signs, and to undergo TLC counseling. Metabolic parameters were measured before and after intervention.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Medical Branch, Galveston
Collaborators:
Pfizer
University of Texas Southwestern Medical Center
Treatments:
Amlodipine, atorvastatin drug combination